1. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Issue 7 (25th March 2022) Authors: Vital, Edward M; Merrill, Joan T; Morand, Eric F; Furie, Richard A; Bruce, Ian N; Tanaka, Yoshiya; Manzi, Susan; Kalunian, Kenneth C; Kalyani, Rubana N; Streicher, Katie; Abreu, Gabriel; Tummala, Raj Journal: Annals of the rheumatic diseases Issue: Volume 81:Issue 7(2022) Page Start: 951 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. (July 2021) Authors: Furie, Richard; Morand, Eric F; Askanase, Anca D; Vital, Edward M; Merrill, Joan T; Kalyani, Rubana N; Abreu, Gabriel; Pineda, Lilia; Tummala, Raj Journal: Lupus Issue: Volume 30:Number 8(2021) Page Start: 1254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. O24 Flare assessments in patients with active systemic lupus erythematosus (SLE) treated with anifrolumab in 2 phase 3 trials. (23rd March 2020) Authors: Furie, Richard; Morand, Eric F; Askanase, Anca; Vital, Ed; Kalyani, Rubana N; Abreu, Gabriel; Pineda, Lilia; Tummala, Raj Journal: Lupus science & medicine Issue: Volume 7(2020)Supplement 1 Page Start: A19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. O25 Efficacy of anifrolumab in active systemic lupus erythematosus (SLE): patient subgroup analysis of BICLA response in 2 phase 3 trials. (23rd March 2020) Authors: Morand, Eric F; Furie, Richard; Tanaka, Yoshiya; Kalyani, Rubana N; Abreu, Gabriel; Pineda, Lilia; Tummala, Raj Journal: Lupus science & medicine Issue: Volume 7(2020)Supplement 1 Page Start: A20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P186 Early and sustained responses with anifrolumab in patients with systemic lupus erythematosus (SLE) in 2 phase 3 trials. (23rd March 2020) Authors: Morand, Eric F; Furie, Richard; Bruce, Ian; Kalunian, Kenneth C; Kalyani, Rubana N; Abreu, Gabriel; Pineda, Lilia; Tummala, Raj Journal: Lupus science & medicine Issue: Volume 7(2020)Supplement 1 Page Start: A120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Issue 1 (17th February 2021) Authors: Tummala, Raj; Abreu, Gabriel; Pineda, Lilia; Michaels, M Alex; Kalyani, Rubana N; Furie, Richard A; Morand, Eric F Journal: Lupus science & medicine Issue: Volume 8:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗